PL2091965T3 - Szczepionki peptydowe przeciwko nowotworom z ekspresją polipeptydów MPHOSPH1 lub DEPDC1 - Google Patents

Szczepionki peptydowe przeciwko nowotworom z ekspresją polipeptydów MPHOSPH1 lub DEPDC1

Info

Publication number
PL2091965T3
PL2091965T3 PL07827901T PL07827901T PL2091965T3 PL 2091965 T3 PL2091965 T3 PL 2091965T3 PL 07827901 T PL07827901 T PL 07827901T PL 07827901 T PL07827901 T PL 07827901T PL 2091965 T3 PL2091965 T3 PL 2091965T3
Authority
PL
Poland
Prior art keywords
vaccines against
against tumors
peptide vaccines
tumors expressing
expressing mphosph1
Prior art date
Application number
PL07827901T
Other languages
English (en)
Inventor
Tomoaki Fujioka
Yusuke Nakamura
Takuya Tsunoda
Ryuji Osawa
Midori Shida
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of PL2091965T3 publication Critical patent/PL2091965T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Reproductive Health (AREA)
PL07827901T 2006-10-17 2007-10-16 Szczepionki peptydowe przeciwko nowotworom z ekspresją polipeptydów MPHOSPH1 lub DEPDC1 PL2091965T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85257506P 2006-10-17 2006-10-17
EP07827901.5A EP2091965B9 (en) 2006-10-17 2007-10-16 Peptide vaccines for cancers expressing mphosph1 or depdc1 polypeptides
PCT/JP2007/001122 WO2008047473A1 (en) 2006-10-17 2007-10-16 Peptide vaccines for cancers expressing mphosph1 or depdc1 polypeptides

Publications (1)

Publication Number Publication Date
PL2091965T3 true PL2091965T3 (pl) 2013-10-31

Family

ID=39313729

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07827901T PL2091965T3 (pl) 2006-10-17 2007-10-16 Szczepionki peptydowe przeciwko nowotworom z ekspresją polipeptydów MPHOSPH1 lub DEPDC1

Country Status (17)

Country Link
US (5) US8557955B2 (pl)
EP (7) EP2687541A1 (pl)
JP (2) JP5339292B2 (pl)
KR (4) KR101454287B1 (pl)
CN (5) CN102850433B (pl)
AU (1) AU2007311395B2 (pl)
BR (1) BRPI0717651A2 (pl)
CA (2) CA2667030C (pl)
DK (1) DK2091965T3 (pl)
ES (4) ES2545817T3 (pl)
IL (4) IL198186A (pl)
MX (1) MX2009004147A (pl)
PL (1) PL2091965T3 (pl)
PT (1) PT2091965E (pl)
RU (1) RU2469044C2 (pl)
SG (2) SG175566A1 (pl)
WO (1) WO2008047473A1 (pl)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2011885B1 (en) 2005-02-10 2015-04-22 Oncotherapy Science, Inc. Method of diagnosing bladder cancer
UA100127C2 (ru) * 2007-08-20 2012-11-26 Онкотерапи Саенс, Инк. Пептид cdh3 и лекарственное средство, содержащее его
EP2362904B1 (en) * 2008-08-28 2016-11-16 Oncotherapy Science, Inc. Method of screening compounds for use in inhibiting depdc1 - znf224 binding
RU2011140168A (ru) * 2009-03-04 2013-04-10 Онкотерапии Сайенс, Инк. Пептиды vangl1 и содержащие их вакцины
TW201211250A (en) * 2010-09-07 2012-03-16 Oncotherapy Science Inc VANGL1 peptides and vaccines including the same
DK2742133T3 (en) * 2011-08-12 2017-12-04 Oncotherapy Science Inc MPHOSPH1 PEPTIDES AND VACCINES CONTAINING THESE
JP2013058294A (ja) * 2011-09-09 2013-03-28 Toshiba Corp 磁気記録媒体及び磁気記録媒体の製造方法
CA2865033C (en) 2012-02-23 2021-11-02 Stage Cell Therapeutics Gmbh Chromatographic isolation of cells and other complex biological materials
US20150359864A1 (en) * 2012-03-09 2015-12-17 Oncotherapy Science, Inc. Pharmaceutical composition containing peptides
JP6041297B2 (ja) * 2012-08-24 2016-12-07 国立大学法人山口大学 犬リンパ腫の診断方法及び診断キット
RU2693088C2 (ru) * 2013-03-13 2019-07-01 Чжун ЛИ Микровезикула и способ ее получения
CN116656605A (zh) 2014-04-16 2023-08-29 朱诺治疗有限公司 用于扩增细胞群的方法、试剂盒及装置
EP3205661B1 (en) 2014-10-07 2021-07-07 Cytlimic Inc. Hsp70-derived immunity inducing peptide
WO2016080367A1 (ja) * 2014-11-18 2016-05-26 塩野義製薬株式会社 安定化されたペプチド組成物
AU2016230125B2 (en) 2015-03-09 2020-07-16 Nec Corporation Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using same, immunity inducer, and method for producing antigen-presenting cells
EP3281641B1 (en) 2015-04-07 2020-12-16 Cytlimic Inc. Adjuvant for cancer vaccines
CN112961213A (zh) * 2015-08-12 2021-06-15 肿瘤疗法科学股份有限公司 Depdc1衍生的肽和包含它们的疫苗
CA3000808A1 (en) * 2015-10-08 2017-04-13 Sachiko YAMASHITA Mphosph1-derived peptide, and vaccine including same
MA45488A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés, kits et appareil de culture de cellules
MA45489A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés de culture de cellules, kits et appareil associés
AU2016341527B2 (en) 2015-10-22 2023-04-27 Juno Therapeutics Gmbh Methods, kits, agents and apparatuses for transduction
BR112019006075A2 (pt) 2016-10-11 2019-06-18 Cytlimic Inc medicamento
WO2018092755A1 (en) * 2016-11-18 2018-05-24 Oncotherapy Science, Inc. Mphosph1 epitope peptides for th1 cells and vaccines containing the same
TW201831502A (zh) * 2016-11-18 2018-09-01 日商腫瘤療法 科學股份有限公司 對於ｔｈ１細胞的ｄｅｐｄｃ１抗原決定位胜肽及包含其之疫苗
CN109923121B (zh) * 2016-11-22 2022-12-23 武汉华大吉诺因生物科技有限公司 多肽及其应用
HRP20220605T1 (hr) 2017-01-25 2022-07-08 Ose Immunotherapeutics Postupak za proizvodnju stabilne emulzije za isporuku peptida
EP4647493A2 (en) 2017-04-27 2025-11-12 Juno Therapeutics, Inc. Oligomeric particle reagents and methods of use thereof
FI3652606T3 (fi) * 2017-07-12 2023-03-16 Nouscom Ag Jaettuihin tuumorineoantigeeneihin perustuva yleisrokote epästabiilien mikrosatelliitti (msi) -syöpien ennaltaehkäisyyn ja hoitoon
AU2018384824B2 (en) 2017-12-13 2022-08-04 Inovio Pharmaceuticals, Inc. Cancer vaccines targeting LEMD1 and uses thereof
CN109932510B (zh) * 2017-12-18 2022-07-12 天津云检医学检验所有限公司 一种宫颈癌生物标志物及其检测试剂盒
CN112142824B (zh) * 2019-06-27 2022-03-11 深圳市东贵博康生化科技有限公司 具有诱导细胞毒性t淋巴细胞能力的多肽及其应用
WO2021060343A1 (ja) * 2019-09-24 2021-04-01 オンコセラピー・サイエンス株式会社 Ｕｒｌｃ１０由来ペプチドまたはｄｅｐｄｃ１由来ペプチドを認識するヒトｔ細胞が発現するｔ細胞受容体

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
RU94038427A (ru) 1991-08-26 1996-10-20 Сайтел Корпорейшн (US) Пептиды, конъюгаты, фармацевтические композиции, способы лечения, способ идентификации
CA2115839C (en) 1991-08-26 2010-06-01 Maria A. Vitiello Hla-restricted hepatitis b virus ctl epitopes
WO2003040165A2 (en) * 2000-10-19 2003-05-15 Epimmune Inc. Hla class i and ii binding peptides and their uses
EP0689455A4 (en) * 1993-03-11 1997-07-23 Univ Southern California THERAPEUTIC STRATEGIES FOR THE TREATMENT OF IMMUNO-INFECTIOUS GROUP VIRAL INFECTIONS
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
US20030198642A1 (en) 1995-08-03 2003-10-23 Johannes J. Geuze Cell derived antigen presenting vesicles
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
CA2262006A1 (en) 1996-07-26 1998-02-05 Sloan-Kettering Institute For Cancer Research Method and reagents for genetic immunization
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
US7001999B1 (en) * 1998-04-15 2006-02-21 Ludwig Institute For Cancer Research Tumor associated nucleic acids and uses therefor
HK1039782B (en) * 1998-09-30 2008-11-14 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
US20040241726A1 (en) * 1999-01-06 2004-12-02 Chondrogene Limited Method for the detection of allergies related gene transcripts in blood
US20050123938A1 (en) 1999-01-06 2005-06-09 Chondrogene Limited Method for the detection of osteoarthritis related gene transcripts in blood
US6291663B1 (en) * 1999-03-03 2001-09-18 Board Of Trustees Of The University Of Arkansas TADG-12: a novel transmembrane serine protease overexpressed in a ovarian carcinoma
US7030215B2 (en) * 1999-03-24 2006-04-18 Sangamo Biosciences, Inc. Position dependent recognition of GNN nucleotide triplets by zinc fingers
WO2000073801A2 (en) * 1999-05-28 2000-12-07 Ludwig Institute For Cancer Research Breast, gastric and prostate cancer associated antigens and uses therefor
EP1311675B1 (en) 2000-08-22 2007-02-07 Agensys, Inc. Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers
CA2425827A1 (en) 2000-10-12 2002-04-18 Hyseq, Inc. Novel nucleic acids and polypeptides
US7919467B2 (en) 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US7083789B2 (en) * 2000-12-04 2006-08-01 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
AU2003207795B2 (en) * 2002-01-31 2009-01-08 Wyeth Aggrecanase molecules
WO2003083074A2 (en) 2002-03-28 2003-10-09 Idec Pharmaceuticals Corporation Novel gene targets and ligands that bind thereto for treatment and diagnosis of colon carcinomas
US20060024692A1 (en) * 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
TW200413725A (en) 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
WO2005007090A2 (en) 2003-07-03 2005-01-27 President And Fellows Of Harvard College Inhibitors of the map kinase pathway
WO2006031221A1 (en) 2004-09-13 2006-03-23 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Compositions comprising t cell receptors and methods of use thereof
EP2011885B1 (en) 2005-02-10 2015-04-22 Oncotherapy Science, Inc. Method of diagnosing bladder cancer
JP2006302684A (ja) 2005-04-21 2006-11-02 D D K Ltd カードコネクタ
EP2295570A1 (en) * 2005-07-27 2011-03-16 Oncotherapy Science, Inc. Method of diagnosing small cell lung cancer
CN101287831B (zh) 2005-09-13 2013-05-15 国立大学法人三重大学 T细胞受体和编码该受体的核酸
US20070099251A1 (en) * 2005-10-17 2007-05-03 Institute For Systems Biology Tissue-and serum-derived glycoproteins and methods of their use
TWM336439U (en) * 2008-02-14 2008-07-11 Optivision Technology Inc Diffuser capable of light condensing
EP2362904B1 (en) * 2008-08-28 2016-11-16 Oncotherapy Science, Inc. Method of screening compounds for use in inhibiting depdc1 - znf224 binding
DK2742133T3 (en) 2011-08-12 2017-12-04 Oncotherapy Science Inc MPHOSPH1 PEPTIDES AND VACCINES CONTAINING THESE

Also Published As

Publication number Publication date
HK1131169A1 (en) 2010-01-15
IL216712A (en) 2017-07-31
ES2545818T3 (es) 2015-09-16
US20120282286A1 (en) 2012-11-08
PT2091965E (pt) 2013-06-11
RU2009118432A (ru) 2010-11-27
KR20140057681A (ko) 2014-05-13
ES2415958T3 (es) 2013-07-29
EP2476698B1 (en) 2015-06-17
CA2667030C (en) 2016-03-15
EP2476697B1 (en) 2015-06-17
ES2545457T3 (es) 2015-09-11
US9545437B2 (en) 2017-01-17
US20100028373A1 (en) 2010-02-04
IL216712A0 (en) 2012-01-31
EP2476697A2 (en) 2012-07-18
MX2009004147A (es) 2009-06-15
EP2091965B9 (en) 2013-09-25
CN101568550B (zh) 2012-12-26
US20150231222A1 (en) 2015-08-20
KR20150015042A (ko) 2015-02-09
IL198186A0 (en) 2011-08-01
EP2476699A3 (en) 2013-11-27
HK1171026A1 (en) 2013-03-15
KR101454287B1 (ko) 2014-11-04
KR101527473B1 (ko) 2015-06-17
CA2667030A1 (en) 2008-04-24
EP2476698A2 (en) 2012-07-18
EP2687541A1 (en) 2014-01-22
CA2915560A1 (en) 2008-04-24
DK2091965T3 (da) 2013-08-05
EP2091965A4 (en) 2011-02-16
JP5339292B2 (ja) 2013-11-13
SG175566A1 (en) 2011-11-28
EP2091965B1 (en) 2013-05-15
EP2476699B1 (en) 2015-06-17
US8653234B2 (en) 2014-02-18
CN102850435A (zh) 2013-01-02
CN102850434A (zh) 2013-01-02
EP2476699A2 (en) 2012-07-18
KR20140104057A (ko) 2014-08-27
EP2695895A1 (en) 2014-02-12
ES2545817T3 (es) 2015-09-16
US20120288514A1 (en) 2012-11-15
WO2008047473A1 (en) 2008-04-24
CN102850433B (zh) 2016-03-02
JP2013116115A (ja) 2013-06-13
US8552146B2 (en) 2013-10-08
CN105693843A (zh) 2016-06-22
US9017688B2 (en) 2015-04-28
HK1171025A1 (en) 2013-03-15
US20130129759A1 (en) 2013-05-23
RU2469044C2 (ru) 2012-12-10
KR101543622B1 (ko) 2015-08-11
CN102850434B (zh) 2016-04-13
CN102850433A (zh) 2013-01-02
CN101568550A (zh) 2009-10-28
AU2007311395A1 (en) 2008-04-24
CN102850435B (zh) 2016-02-17
EP2091965A1 (en) 2009-08-26
HK1171024A1 (en) 2013-03-15
SG10201502098YA (en) 2015-05-28
EP2687540A1 (en) 2014-01-22
AU2007311395B2 (en) 2013-02-21
KR101493773B1 (ko) 2015-03-03
IL222925A0 (en) 2012-12-31
EP2476698A3 (en) 2013-11-27
US8557955B2 (en) 2013-10-15
EP2476697A3 (en) 2013-11-27
IL198186A (en) 2017-05-29
BRPI0717651A2 (pt) 2013-12-24
KR20090083378A (ko) 2009-08-03
IL216713A0 (en) 2012-01-31
JP2010506826A (ja) 2010-03-04

Similar Documents

Publication Publication Date Title
PL2091965T3 (pl) Szczepionki peptydowe przeciwko nowotworom z ekspresją polipeptydów MPHOSPH1 lub DEPDC1
DK2035447T3 (da) Polypeptid
PL2465864T3 (pl) Szczepionki z peptydem pochodzącym z Eph4
EP2118122A4 (en) NOVEL ANTIMICROBIAL PEPTIDES
DK3178835T3 (da) Forlængede rekombinante polypeptider og sammensætninger omfattende samme
EP2278994A4 (en) Flagellin POLYPEPTIDE VACCINES
EP2093287A4 (en) PEPTIDE BINDER IGG
BRPI0907363A2 (pt) Métodos e composições relativos a peptídeos e proteínas com elementos de c-terminal
DK2147096T3 (da) Modificerede faktor-VII-polypeptider og anvendelser deraf
DK2390265T3 (da) Insulinotropisk peptidderivat med modificeret N-terminal aminosyre
DK3118221T3 (da) Proteiner
EP2170362A4 (en) Lyophilized anti-lipid composition
IL197094A0 (en) Immunogenic pcpa polypeptides and uses thereof
EP2020483A4 (en) COMPRESSOR WITH INCORPORATED EXPANSION DEVICE
BRPI0911743A2 (pt) "peptídeo"
DK2035451T3 (da) Insulinoptrop peptidsyntese
GB0708376D0 (en) Novel polypeptides and uses thereof
BRPI0814763A2 (pt) Peptídeos imunomoduladores
ZA201000283B (en) Reinigung pegylierter polypeptide
DK2176284T3 (da) Lantibiotika og anvendelser deraf
BRPI0814127A2 (pt) Polipeptídeos imunegênicos e anticorpos monoclonais
DK2666854T3 (da) Rekombinante elastase-proteiner og fremgangsmåder til fremstilling og anvendelse deraf
EP2300033A4 (en) CONJUGATES OF COLLAGEN PEPTIDE AND USES THEREOF
DK2207790T3 (da) Biologisk aktive C-terminalt argininholdige peptider
EP2285827A4 (en) PEPTIDES AND THEIR USES